Clinical scenario

Recurrent or recalcitrant erythematous nodules on the pretibial area persist despite a first-line course of oral potassium iodide. This protocol defines the structured next step when initial management does not achieve clearance.

Previous treatment — goal not reached

Prior therapy: Oral potassium iodide

Target that was not met: Resolution of erythematous nodules on the pretibial area

Failure to reach this endpoint is the escalation trigger for the second-line protocol below.

What the next-line approach involves

Treatment goal: Resolution of recurrent or recalcitrant erythematous nodules on the pretibial area.

Management at this stage draws on oral antimicrobial and anti-inflammatory agents, with corticosteroid therapy reserved for more severe presentations. A localised intervention option also exists for particularly recalcitrant nodules. The full regimen, drug selection criteria, and evidence summary are available in the complete protocol.

References

DOI: 10.1007/s40257-021-00592-w

Doses of 50–75 mg/day have been used with caution because of its potential side effects, including methemoglobinemia, hemolysis, agranulocytosis, and peripheral motor neuropathy.
Some patients respond to hydroxychloroquine 200 mg twice daily.
Tetracyclines, such as minocycline 100 mg twice daily and tetracycline 500 mg every 6–12 h, have been considered as an option for chronic EN.
Prednisone 40 mg/day has been used in severe conditions.
For recalcitrant nodules, intralesional triamcinolone acetonide 5 mg/mL, injected to the center of an inflamed lesion, has been used.
An underlying infection or malignancy should be ruled out before using corticosteroids.

View source ↗

Primary Erythema Nodosum Not Responding to Potassium Iodide

References